This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John G. Fort, MD, MBA; Howard D. Hoffman, MD
Chicago, Ill

Arch Intern Med. 1995;155(13):1448.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Cost-effectiveness in medicine is an important issue for health care practitioners in particular and to society in general. We welcome scientific discourse on this issue so that the medical community can make informed decisions. There are several issues that we feel need clarification in the recent article by Stucki et al¹ regarding the cost-effectiveness of misoprostol.

The authors suggest that misoprostol (Cytotec) has been promoted as a "routine" medication for patients who are receiving long-term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs). On the contrary, misoprostol is indicated for the prevention of NSAID-induced ulcers in patients who have certain risk factors such as advanced age, history of peptic ulcer disease, and the presence of comorbid conditions.^2,3 Moreover, the use of a combination of a NSAID and misoprostol (Arthrotec, available outside the United States) is not intended to promulgate the "routine" use of misoprostol, but rather to improve compliance.

A . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?